Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study
- 23 July 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (11) , 2870-2882
Abstract
Aims: Programmed cell death receptor (ligand)‐1 inhibitors (PD‐(L)1), as the preferred immunotherapy, have been widely used in the Chinese mainland and drug‐induced liver injury (DILI) has been reported. The study aimed to investigate the clinical features or risk factors for immunotherapy‐related DILI.Methods: Patients who received PD‐(L)1 inhibitors from January 2020 to July 2021 were retrospectively reviewed. The likelihood of DILI was adjudicated by the Roussel‐Uclaf causality assessment.Results: A total of 1175 patients were included in the study and 89 patients (7.6%) developed DILI, of which 12 (13.5%) progressed to acute liver failure (ALF) and three (3.4%) died. Among the DILI population, 56 (62.9%) had a cholestatic pattern and exhibited a prolonged treatment course and duration for resolution compared to the hepatocellular and mixed patterns. Hepatocellular carcinoma (HCC), hepatitis B virus (HBV) and abnormal baseline of alkaline phosphatase (ALP) had increased risks of DILI by 2.1‐fold (95% confidence interval [CI], 1.231–3.621), 1.9‐fold [95% CI, 1.123–3.325] and 2.1‐fold [95% CI, 1.317–3.508], respectively. The model for end‐stage liver disease (MELD) score had a c‐statistic of 0.894 (95% CI, 0.778–1.000) with a sensitivity of 67% and a specificity of 95% for poor outcomes. COX analysis showed that the MELD ≥ 18 was predictive of immunotherapy‐related ALF or death.Conclusions: PD‐(L)1 inhibitor‐related liver injury manifests primarily as a cholestatic pattern, on which corticosteroid treatment has minimal effect compared to hepatocellular and mixed patterns. MELD score ≥ 18 at the time of liver injury performed best in the prediction of ALF or death in immune checkpoint inhibitor (ICI)‐related DILI.Keywords
Funding Information
- National Natural Science Foundation of China (82003995)
This publication has 28 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2020
- Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic MelanomaHepatology, 2019
- HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infectionJHEP Reports, 2019
- Hepatotoxicity of immune check point inhibitors: Approach and managementDigestive and Liver Disease, 2019
- EASL Clinical Practice Guidelines: Drug-induced liver injuryJournal of Hepatology, 2019
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitorsJournal of Hepatology, 2018
- Features and outcomes from a retrospective study of 570 hospitalized Chinese patients with drug-induced liver injuryClinics and Research in Hepatology and Gastroenterology, 2018
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- The model for end-stage liver disease (MELD)Hepatology, 2007